Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941012 | 0.89 | NR1H2 (0.43) | NR1H2CYP4A11CYP4F2GPR119RORC | |
| SCHEMBL4938707 | 0.87 | NR1H2 (0.37) | NR1H2GPR119RORCPKMHDAC1 | |
| SCHEMBL4937394 | 0.83 | REN (0.46) | — | |
| SCHEMBL4934280 | 0.80 | NR1H2 (0.41) | NR1H2CYP4A11CYP4F2GPR119RORC | |
| SCHEMBL5274358 | 0.80 | NR1H2 (0.45) | NR1H2CYP4A11CYP4F2GPR119HDAC1 | |
| SCHEMBL4939372 | 0.77 | PKM (0.36) | NR1H2GPR119PKMHDAC1HDAC6 | |
| SCHEMBL4932897 | 0.73 | REN (0.46) | — | |
| SCHEMBL4930538 | 0.73 | REN (0.45) | RORC | |
| SCHEMBL19176107 | 0.71 | CHRM5 (0.45) | NR1H2 | |
| SCHEMBL9350724 | 0.69 | GPR119 (0.47) | NR1H2GPR119HDAC1HDAC6PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
| CN-1863773-A | Tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-15 | — | — | CN | disclosed |
| EP-1673341-A1 | TETRAHYDROPYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040120-A1 | TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | REN, AGTR1, CBR1 | NR1H2 797/4885CYP4A11 306/4885CYP4F2 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.